


Research may help combat the deadly gastrointestinal infection *Clostridium difficile*

11 May 2018



Clostridium difficile (*C. diff*) causes severe gastrointestinal tract infections. The 3-D structure shows how a key *C. diff* toxin, TcdB (in orange), recognizes the human Frizzled protein (in green) as its receptor to invade cells, leading to damage in the intestinal barrier. Shown in the background is immunofluorescent staining of the healthy mouse cecum tissue (left) and the one damaged by TcdB (right). Credit: Rongsheng Jin, University of California, Irvine

Researchers from the University of California, Irvine and Harvard University have discovered how the *Clostridium difficile* toxin B (TcdB) recognizes the human Frizzled protein, the receptor it uses to invade intestinal cells and lead to deadly gastrointestinal infections. The findings, published today in *Science*, could pave the way for new *C. diff* antitoxins and also show potential for the development of novel anti-cancer drugs.

In a *C. diff* infection (CDI), TcdB targets colonic epithelia and binds to what are called Frizzled (FZD) receptors. Researchers in the labs of Rongsheng Jin, Ph.D., professor of physiology & biophysics from the UCI School of Medicine, and Min Dong, Ph.D., from Boston Children's Hospital—Harvard Medical School, found that

during this binding process, the toxin locks certain lipid molecules in FZD, which block critical Wnt signaling that regulates renewal of colonic stem cells and differentiation of the colonic epithelium.

"This toxin is indeed very smart. It takes advantage of an important lipid that FZD uses for its own function, to improve its binding affinity and specificity to FZD," said Jin, "However, the need for this lipid also exposes a vulnerability of TcdB that could be exploited to develop antitoxins that block toxin-receptor recognition."

Jin and Dong believe that the novel FZD-antagonizing mechanism exploited by toxin B could be used to turn this deadly [toxin](#) into a potential pharmacological tool for research and therapeutic applications, including anti-cancer drugs.

The team's preliminary data show that a non-toxic fragment of TcdB that they identified could significantly inhibit the growth of some cancer cells with dysregulation in Wnt signaling. A patent application has been filed.

Clostridium difficile causes severe gastrointestinal tract infections and tops the Center for Disease Control and Prevention's [list of urgent drug-resistant threats](#). *Clostridium difficile* infection has become the most common cause of antibiotic-associated diarrhea and gastroenteritis-associated death in developed countries, accounting for half-million cases and 29,000 deaths annually in the United States. It is classified as one of the top three "urgent threats" by the CDC.

More information: Peng Chen et al. Structural basis for recognition of frizzled proteins by *Clostridium difficile* toxin B, *Science* (2018). [DOI: 10.1126/science.aar1999](https://doi.org/10.1126/science.aar1999)

Provided by University of California, Irvine

APA citation: Research may help combat the deadly gastrointestinal infection *Clostridium difficile* (2018, May 11) retrieved 12 July 2022 from <https://medicalxpress.com/news/2018-05-combat-deadly-gastrointestinal-infection-clostridium.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.